Oxford Vaccine Group
Welcome,         Profile    Billing    Logout  
 10 Trials 
16 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Snape, Matthew D
NCT03880669: The 6-in-1 Vaccine Study

Not yet recruiting
4
240
Europe
Infanrix hexa or Vaxelis
University of Oxford, MCM Vaccines B.V.
Vaccination; Infection
10/21
04/22
COMBAT-COVID, NCT05162482: Combination Assessment Trial of COVID-19 Vaccines

Not yet recruiting
2
1680
RoW
BIBP (CNBG, Sinopharm) WIV, CanSinoBIO, AstraZeneca ChAdOx
Aga Khan University Hospital, Pakistan, Coalition for Epidemic Preparedness Innovations, University of Oxford, International Vaccine Institute, Harvard Medical School (HMS and HSDM), Chughtai Lab, National Institute of Health, Pakistan
COVID 19 Vaccine
06/24
06/24
STORY, NCT04061382: Sero-epidemiological Survey of England in 2019/2020 - COVID-19

Active, not recruiting
N/A
2959
Europe
Venepuncture, Oral fluid swab
University of Oxford
Serogroup C Meningococcal Meningitis, Diphtheria, COVID-19
06/21
06/22
Pollard, Andrew
NCT04536051: A Study of a Candidate COVID-19 Vaccine (COV003)

Recruiting
3
10300
RoW
ChAdOx1 nCoV-19 single dose + paracetamol, MenACWY single dose + paracetamol, ChAdOx1 nCoV-19 two dose + paracetamol, MenACWY prime & saline placebo boost + paracetamol
University of Oxford
Coronavirus
09/21
09/21
NCT04400838 / 2020-001228-32: Investigating a Vaccine Against COVID-19

Active, not recruiting
2/3
12390
Europe
ChAdOx1 nCoV-19 (Abs 260), MenACWY vaccine, Menveo, Nimenrix, ChAdOx1 nCoV-19 (Abs 260) + 2.2x10^10vp (qPCR) boost, Two dose MenACWY vaccine, ChAdOx1 nCoV-19 (qPCR), ChAdOx1 nCoV-19 0.5mL prime plus boost, Two dose MenACWY vaccine min. 4 weeks apart, Two dose ChAdOx1 nCoV-19/Covishield 0.5mL, Two dose ChAdOx1 nCoV-19/Covishield 0.25mL & 0.5mL
University of Oxford
Coronavirus
03/24
03/24
NCT01405521 / 2011-000381-35: Understanding Typhoid Disease After Vaccination

Completed
2
99
Europe
Vaccine placebo (excipients only), Ty21a, Vivotif, M10ZH09 vaccine, Typhella
University of Oxford, Wellcome Trust, Imperial College London, University of Maryland
Typhoid Fever, Enteric Fever, Typhoid
12/15
05/22
COMBAT-COVID, NCT05162482: Combination Assessment Trial of COVID-19 Vaccines

Not yet recruiting
2
1680
RoW
BIBP (CNBG, Sinopharm) WIV, CanSinoBIO, AstraZeneca ChAdOx
Aga Khan University Hospital, Pakistan, Coalition for Epidemic Preparedness Innovations, University of Oxford, International Vaccine Institute, Harvard Medical School (HMS and HSDM), Chughtai Lab, National Institute of Health, Pakistan
COVID 19 Vaccine
06/24
06/24
NCT04324606: A Study of a Candidate COVID-19 Vaccine (COV001)

Active, not recruiting
1/2
1090
Europe
ChAdOx1 nCoV-19, MenACWY, ChAdOx1 nCoV-19 full boost, ChAdOx1 nCoV-19 half boost, MenACWY boost, Paracetamol, ChAdOx1 nCoV-19 0.5mL boost, ChAdOx1 nCoV-19 0.5mL (3.5-6.5x10^10vp) late vaccine (LV), ChAdOx1 nCoV-19 0.5mL (3.5-6.5x10^10vp) late vaccine two (LVT)
University of Oxford
Coronavirus
03/24
03/24
TYGER, NCT03067961: Investigating Typhoid Fever Pathogenesis

Active, not recruiting
N/A
40
Europe
Salmonella Typhi (S. Typhi)
University of Oxford, Bill and Melinda Gates Foundation, Yale University
Salmonella Typhi Infection
08/18
09/22
NCT01945307: Complement 2: Blood Donations to Develop Vaccines Against Infectious Diseases

Completed
N/A
101
Europe
University of Oxford, Wellcome Trust
Complement Mediated Bacterial Killing in Healthy Adults
03/23
03/23
NCT03756766: Understanding RSV: Severe Disease and the Long Term Consequences

Active, not recruiting
N/A
315
Europe
RSV point of care testing, Venepuncture, Nasopharyngeal swabs, stool sample, Urine sample
University of Oxford, Innovative Medicines Initiative, Respiratory syncytial virus consortium in Europe
Respiratory Syncytial Virus (RSV)
11/26
11/26
Kelly, Dominic
NCT05082285 / 2021-001367-24: A Study on the Safety, Tolerability and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Infants

Active, not recruiting
2
724
Europe, RoW
MenABCWY-2Gen low dose vaccine, MenABCWY-2Gen high dose vaccine, MenABCWY-1Gen vaccine, MenB vaccine, Bexsero, MenACWY-TT vaccine, Nimenrix
GlaxoSmithKline
Infections, Meningococcal
03/25
03/25
NCT05116241: Immunogenicity and Safety of BPZE1 Intranasal Pertussis Vaccine in Healthy School-age Children

Active, not recruiting
2
360
Europe, RoW
BPZE1 pertussis vaccine and placebo, BPZE1 pertussis vaccine and Boostrix, Placebo and Boostrix
ILiAD Biotechnologies
Bordetella Pertussis, Whooping Cough
04/24
04/24
Ramasamy, Maheshi
CHAMPION-1, NCT05461131: Pertussis Challenge Study in Adults Vaccinated With BPZE1

Completed
2
53
Europe
BPZE1, Placebo, Azithromycin, Bordetella Pertussis Challenge Strain
ILiAD Biotechnologies
Pertussis/Whooping Cough, Bordetella Pertussis, Whooping Cough
07/23
10/23
Stoilova, Bilyana
NCT05116241: Immunogenicity and Safety of BPZE1 Intranasal Pertussis Vaccine in Healthy School-age Children

Active, not recruiting
2
360
Europe, RoW
BPZE1 pertussis vaccine and placebo, BPZE1 pertussis vaccine and Boostrix, Placebo and Boostrix
ILiAD Biotechnologies
Bordetella Pertussis, Whooping Cough
04/24
04/24
Solorzano, Carla
CHAMPION-1, NCT05461131: Pertussis Challenge Study in Adults Vaccinated With BPZE1

Completed
2
53
Europe
BPZE1, Placebo, Azithromycin, Bordetella Pertussis Challenge Strain
ILiAD Biotechnologies
Pertussis/Whooping Cough, Bordetella Pertussis, Whooping Cough
07/23
10/23

Download Options